Get the Stockscreener App
175.58
2.37%
4.06
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $175.58, with a volume of 12.92M.
It is up +2.37% in the last 24 hours and up +4.66% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
See More
Previous Close:
$171.52
Open:
$171.794
24h Volume:
12.92M
Relative Volume:
2.28
Market Cap:
$310.27B
Revenue:
$55.53B
Net Income/Loss:
$5.12B
P/E Ratio:
48.10
EPS:
3.65
Net Cash Flow:
$15.62B
1W Performance:
+1.27%
1M Performance:
+4.66%
6M Performance:
+2.00%
1Y Performance:
+15.75%
1-Day Range:
$170.66
$176.80
1-Week Range:
$170.21
$176.80
52-Week Range:
$151.29
$207.32
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
175.58 | 310.27B | 55.53B | 5.12B | 15.62B | 2.88 |
|
LLY
Lilly Eli Co
|
767.76 | 690.46B | 40.86B | 8.37B | -2.28B | 9.25 |
|
NVO
Novo Nordisk Adr
|
85.00 | 377.54B | 39.36B | 13.79B | 9.83B | 3.086 |
|
JNJ
Johnson Johnson
|
144.47 | 347.83B | 87.70B | 14.68B | 19.03B | 6.05 |
|
MRK
Merck Co Inc
|
98.05 | 248.03B | 63.17B | 12.15B | 14.84B | 4.77 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
Abbvie - Contract Pharma
AbbVie (NYSE:ABBV) Stock Price Up 2%Here's What Happened - MarketBeat
AbbVie, Novartis and drug industry win court battle in larger 340B war - Crain's Chicago Business
Alembic Pharma Gains USFDA Approval for Epilepsy Treatment - Devdiscourse
GLP-1 Receptor Agonist Market Is Booming Worldwide 2024-2031:Verrica Pharmaceuticals,AbbVie Inc,Glenmark - EIN News
AbbVie Inc. stock underperforms Thursday when compared to competitors - MarketWatch
AI & Data Convergence - AbbVie
AbbVie (NYSE:ABBV) Trading Down 0.5% After Insider Selling - MarketBeat
AbbVie acquiring Madison-based Nimble Therapeutics for $200 million - Milwaukee Journal Sentinel
AbbVie's atogepant and onabotulinumtoxinA receive strong recommendations in the newly updated Canadian Headache Society (CHS) Migraine Prevention Guideline - Kilgore News Herald
Is AbbVie Inc. (ABBV) the Safest Dividend Stock to Invest In Now? - Insider Monkey
Acellular Dermal Matrices Market Projected To Witness Substantial Growth, 2024-2031: Stryker Corporation, - EIN News
Abbvie SVP Kevin Buckbee sells stock for $310,032 - Investing.com India
Kevin K. Buckbee Sells 1,800 Shares of AbbVie Inc. (NYSE:ABBV) Stock - MarketBeat
ASH: AbbVie/Genmab Look To Stake Anti-CD20 Bispecific Claim In CLL - Citeline News & Insights
AbbVie Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Novartis, AbbVie Score Win to Block West Virginia Drug Limit Law - Bloomberg Law
AbbVie's SWOT analysis: biopharma giant navigates post-Humira landscape - Investing.com
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know - Yahoo Finance
AbbVie Inc. (NYSE:ABBV) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Biologics Market to See Booming Growth 2024-2031 | AbbVie Inc., - openPR
AbbVie Inc. stock outperforms competitors on strong trading day - MarketWatch
AbbVie's (ABBV) Overweight Rating Reiterated at Piper Sandler Companies - MarketBeat
Bain Sued Over Cerevel Trades Before $8.7 Billion Sale to AbbVie - Bloomberg Law
AbbVie (NYSE:ABBV) Price Target Raised to $220.00 at Piper Sandler - MarketBeat
4 Big Drug Stocks That May Continue to Outperform in 2025 - Yahoo Finance
AbbVie Takes On Pfizer And Merck With Its Next Leg Of Growth. Will AbbVie Stock Come Back? - Yahoo! Voices
Spinal Cord Injury Therapeutics Market Set to Witness Significant Growth by 2024-2031: AbbVie Inc, Pfizer - EIN News
Immunology Market Huge Growth in Future Scope 2024-2031 | AbbVie - openPR
Is AbbVie Ready for a Bullish Turn? - Investing.com
Is AbbVie Ready for a Bullish Turn? - Investing.com
Botulinum Toxin in Urology Market Top PlayersAbbVie Inc., Merz Pharma; Ipsen Pharma; GALDERMA; Allergan PLC. - openPR
AbbVie Stock Volatile On $200M Deal To Buy Nimble Therapeutics: Retail Still Bearish - MSN
AbbVie (ABBV) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance
Why Investors Should Watch AbbVie Inc (ABBV) - See It Market
AbbVie: Pullback Is A Golden Opportunity For Dividend And Growth Investors - Seeking Alpha
AbbVie (ABBV) Acquires Nimble Therapeutics for $200 Million - GuruFocus.com
AbbVie Enters Oversold Territory - Forbes
AbbVie, Novartis Drop Suit Over Kansas Drug Discount Limit Law - Bloomberg Law
ABBV to Acquire Nimble Therapeutics to Strengthen Immunology Pipeline - Yahoo Finance
AbbVie continues deal-making spree with $200M Nimble buy - PharmaLive
AbbVie Continues Deal-Making Spree With $200M Nimble Buy - BioSpace
AbbVie adds psoriasis med with Nimble takeover - pharmaphorum
AbbVie to acquire Nimble Therapeutics for $200m - Yahoo Finance
Alzheimers Drugs Market to See Booming Growth 2024-2031 | - openPR
AbbVie to acquire Nimble Therapeutics in $200m deal - World Pharmaceutical Frontiers
AbbVie Parkinson’s Drug Rejected by FDA After Plant Inspection - MSN
AbbVie Inc. (NYSE:ABBV) Stock Position Lowered by Lord Abbett & CO. LLC - MarketBeat
B. Riley Wealth Advisors Inc. Decreases Stake in AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie (ABBV) Announces Leadership Transition in Financial Department - GuruFocus.com
AbbVie nabs autoimmune diseases specialist Nimble - The Pharma Letter
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.62%
1.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):